Pfizer’s COVID-19 vaccine: Everything you need to know

Drugmakers Pfizer and BioNTech have said their experimental vaccine may be 90 percent effective at preventing COVID-19.

While the Pfizer-BioNTech trial has yet to be peer-reviewed by experts, scientists reacted positively, if cautiously to the results.

It is said that Pfizer and German partner BioNTech SE are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine. The companies said they have so far found no serious safety concerns.

As reported by abcnews, The vaccine, dubbed BNT162b2, involves two jabs, each three weeks apart. In interim results from the companies’ phase 3 clinical trial, which started in July and has more than 43,000 enrolled participants, they reported 94 lab-confirmed COVID-19 infections.

It is said that vaccine lowers your chances of getting sick by 90 per cent, compared to someone who hasn’t been vaccinated.

Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November

Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints

As reported by TOI, They now expect to produce up to 50 million doses or enough vaccine to protect 25 million people this year. Pfizer said it expects to produce up to 1.3 billion doses of the vaccine in 2021.